ListarINIBIC-ICATC - Artigos por tema "Inotrope"

Mostrando ítems 1-3 de 3

    • Inotropic therapy in patients with advanced heart failure: a clinical consensus statement from the Heart Failure Association of the European Society of Cardiology 

      Gustafsson, Finn; Damman, Kevin; Nalbantgil, Sanem; Van Laake, Linda W.; Tops, Laurens F.; Thum, Thomas; Adamopoulos, Stamatis; Bonios, Michael; Coats, Andrew J.S.; Crespo-Leiro, María Generosa; Mehra, Mandeep R.; Filippatos, Gerasimos; Hill, Loreena; Metra, Marco; Jankowska, Ewa; de Jonge, Nicolaas; Kaye, David; Masetti, Marco; Parissis, John; Milicic, Davor; Seferovic, Petar; Rosano, Giuseppe; Ben Gal, Tuvia (John Wiley & Sons, 2023-02-27)
      [Abstract] This clinical consensus statement reviews the use of inotropic support in patients with advanced heart failure. The current guidelines only support use of inotropes in the setting of acute decompensated heart ...

    • Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use 

      Papp, Zoltán; Álvarez, Julián; Bettex, Dominique; Bouchez, Stefan; Brito, Dulce; Černý, Vladimir; Comin-Colet; Comin-Colet, Josep; Crespo-Leiro, María Generosa; Delgado-Jiménez, Juan F.; Édes, István; Eremenko, Alexander; Farmakis, Dimitrios; Fedele, Francesco; Fonseca, Candida; Fruhwald, Sonja; Girardis, Massimo; Guarracino, Fabio; Harjola, Veli-Pekka; Heringlake, Matthias; Herpain, Antoine; Heunks, Leo; Husebye, Tryggve; Ivancan, Višnja; Karason, Kristjan; Kaul, Sundeep; Kivikko, Matti; Kubica, Janek; Masip, Josep; Matskeplishvili, Simon; Mebazaa, Alexandre; Nieminen, Markku S.; Oliva, Fabrizio; Papp, Julius G.; Parissis, John; Parkhomenko, Alexander; Põder, Pentti; Pölzl, Gerhard; Reinecke, Alexander; Ricksten, Sven-Erik; Riha, Hynek; Rudiger, Alain; Sarapohja, Toni; Schwinger, Robert H. G.; Toller, Wolfgang; Tritapepe, Luigi; Tschöpe, Carsten; Wikström, Gerhard; Lewinski, Dirk von; Vrtovec, Bojan; Pollesello, Piero; Agostoni, Piergiuseppe (Wolters Kluwer, 2020-07)
      [Abstract] Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart ...

    • Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: GALACTIC‐HF Baseline Characteristics and Comparison With Contemporary Clinical Trials 

      Teerlink, John R.; Díaz, Rafael; Felker, G. Michael; McMurray, John J.V.; Metra, Marco; Solomon, Scott D.; Adams, Kirkwood F.; Anand, Inder; Arias‐Mendoza, Alexandra; Biering‐Sørensen, Tor; Böhm, Michael; Bonderman, Diana; Cleland, John G.F.; Corbalán, Ramón; Crespo-Leiro, María Generosa; Dahlström, Ulf; Echeverría Correa, Luis E.; Fang, James C.; Filippatos, Gerasimos; Fonseca, Cándida; Goncalvesova, Eva; Goudev, Assen R.; Howlett, Jonathan G.; Lanfear, David E.; Lund, Mayanna; Macdonald, Peter; Mareev, Vyacheslav; Momomura, Shin‐ichi; O'Meara, Eileen; Parkhomenko, Alexander; Ponikowski, Piotr; Ramires, Felix J.A.; Serpytis, Pranas; Sliwa, Karen; Spinar, Jindrich; Suter, Thomas M.; Tomcsanyi, Janos; Vandekerckhove, Hans; Vinereanu, Dragos; Voors, Adriaan A.; Yilmaz, Mehmet B.; Zannad, Faiez; Sharpsten, Lucie; Legg, Jason C.; Abbasi, Siddique A.; Varin, Claire; Malik, Fady I.; Kurtz, Christopher E. (Willey Online Library, 2020-09-20)
      [Abstract] Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach ...